Alaproclate
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Alaproclate (GEA-654) is a psychoactive drug and research chemical that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. Some studies have found that it acts as a noncompetitive NMDA antagonist, but does not have discriminative stimulus properties similar to phencyclidine.[1][2]
References
References
- ↑ Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KE (December 1994). “Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow”. The Journal of Pharmacology and Experimental Therapeutics. 271 (3): 1314–9. PMID 7996440. (Subscription required (help)).
- ↑ Nicholson KL, Balster RL (November 2003). “Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats”. Psychopharmacology (Berlin). 170 (2): 215–24. doi:10.1007/s00213-003-1527-6. PMID 12851738. (Subscription required (help)).
- ↑ Template:Cite doi
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH